Unresectable Hepatocellular Carcinoma (uHCC) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Unresectable Hepatocellular Carcinoma (uHCC) Market Outlook

Thelansis's "Unresectable Hepatocellular Carcinoma (uHCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Unresectable Hepatocellular Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Unresectable Hepatocellular Carcinoma (uHCC): Overview

Unresectable hepatocellular carcinoma (uHCC) represents an advanced, highly aggressive form of primary liver cancer characterized by extensive intrahepatic tumor burden, multifocal disease, macrovascular invasion, or compromised hepatic function that precludes curative interventions such as surgical resection or liver transplantation.

The disease arises predominantly in the setting of chronic liver injury and cirrhosis, driven by etiologies including hepatitis B and C infections, alcohol-related liver disease, and metabolic dysfunction-associated steatotic liver disease (MASLD). Biologically, uHCC is marked by pronounced angiogenesis, immune evasion, and activation of oncogenic signaling pathways.

Clinically, patients often present with progressive hepatic decompensation, including refractory ascites, jaundice, and portal hypertension, contributing to poor prognosis. Given the limited efficacy of cytotoxic chemotherapy and reduced feasibility of locoregional therapies in advanced stages, treatment is primarily systemic.

The therapeutic paradigm has evolved significantly, with frontline treatment shifting toward combination regimens-particularly immune checkpoint inhibitors (PD-1/PD-L1 inhibitors) combined with anti-angiogenic agents (VEGF inhibitors) or CTLA-4 blockade-demonstrating improved survival outcomes and redefining the standard of care.

Key Highlights

• In France, incident cases are projected to increase from 7,874 in 2025 to 8,033 by 2035, indicating marginal growth in disease burden.
• Diagnosis rate remains high at 85.0%, reflecting strong detection capabilities across healthcare systems.
• Treatment rate stands at 76.2%, highlighting a residual gap between diagnosed and treated patients.
• The treatment paradigm has shifted toward immunotherapy-based combinations (IO + anti-VEGF/CTLA-4) as the new standard of care.
• Persistent unmet need exists in post-progression settings and treatment-resistant populations, despite recent therapeutic advances.

Market Overview

• The United Kingdom uHCC market is projected to grow from $49M in 2025 to $71M by 2035, reflecting steady market expansion.
• Market growth is driven by:
• Increasing adoption of high-cost immunotherapy combinations
• Expansion of eligible patient population due to improved diagnosis
• Despite modest epidemiological growth, market value is supported by premium-priced biologics and longer treatment duration.
• Strong reimbursement frameworks in Europe continue to facilitate access to innovative therapies.
• Future growth will depend on next-generation immunotherapies and novel combination strategies targeting resistance mechanisms.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• InnoBM Pharmaceuticals Co., Ltd.
• Chengdu New Radiomedicine Technology Co. LTD.
• BeiGene
• Hoffmann-La Roche
• Beijing Gene Key Life Technology Co., Ltd
• Akeso
• AstraZeneca
• Tvardi Therapeutics, Incorporated
• Genentech, Inc.
• RayzeBio, Inc.
• Shanghai Henlius Biotech